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Introduction: Low plasma glutamine concentration at ICU admission is associated with unfavorable outcomes. The
prediction of plasma glutamine concentration after ICU discharge on outcomes has not been characterized. In the
recent Scandinavian Glutamine Trial, a survival advantage was seen with glutamine supplementation as long as
patients stayed in the ICU. It was therefore hypothesized that the glutamine level may drop at ICU discharge,
indicative of a sustained glutamine deficiency, which may be related to outcome.
Methods: Fully fed ICU patients intravenously supplemented with glutamine for >3 days were studied at ICU
discharge and post ICU. In study A, plasma glutamine level was followed every 5 to 7 days post ICU of the
remaining hospital stay and compared to the level on the day of ICU discharge (n = 63). In study B, plasma
glutamine level 24 to 72 hours after ICU discharge was related to 12-month all-cause mortality (n = 100).
Results: Post-ICU plasma glutamine levels were within normal range and were not found to be predictive for
mortality outcome. Plasma glutamine level at discharge, on the other hand, was within normal limits but higher
in nonsurvivors. In addition, it was adding prediction value to discharge SOFA scores for post-ICU mortality.
Conclusions: Post-ICU glutamine levels are not indicative of glutamine depletion. The relation between plasma
glutamine concentration and glutamine availability during critical illness is not well understood, and needs to be
studied further to define the possible role for glutamine supplementation.Introduction
A low plasma concentration of glutamine at intensive
care unit (ICU) admission is associated with an unfavor-
able outcome [1,2]. A high glutamine concentration at
ICU admission may also communicate a negative predic-
tion [2]. Other reports claim that free glutamine deple-
tion in tissues (during ICU stays) is associated with
unfavorable outcome [3,4]. So the hypothesis - that at
least some critically ill patients may have a shortage of
free glutamine - seems to be valid. Conventional prod-
ucts for enteral feeding of critically ill patients contain
the same amounts of glutamine as ordinary food, while
conventional products for parenteral feeding of these pa-
tients do not contain any glutamine, related to stability
issues. Consequently, supplementation of glutamine was
suggested [5].* Correspondence: marie.smedberg@karolinska.se
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unless otherwise stated.Literature on glutamine supplementation for critically
ill patients is extensive. Meta-analyses suggest a benefi-
cial effect when intravenous (iv) supplementation is
given to ICU patients on parenteral nutrition [6,7]. Re-
ports on enteral supplementation to ICU patients on en-
teral nutrition are less conclusive [6]. Only a few studies
include plasma glutamine concentration measurements
as a possible indicator of individuals with glutamine de-
pletion, which should be the proper target group for
supplementation [8-10]. The rational for supplementing
critically ill patients - without knowledge of their actual
glutamine status - has been that glutamine supplementa-
tion was considered to be without side effects [5,11]. But
recently, a study demonstrated harm when supplying
glutamine in high doses as a part of a pharmaconutrition
concept in the acute phase of critical illness [9], although
the subjects were a selected subgroup that received
hypocaloric nutrition and had two or more organ fail-
ures. So better knowledge of the glutamine status and
whether or not an actual deficiency of glutamine is
present in the individual patient is needed.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ondary outcomes of only patients treated per protocol
that iv glutamine supplementation may improve out-
come during ICU stay [12]. This possible benefit, how-
ever, was not sustained after ICU discharge, which may
be related to that glutamine supplementation was dis-
continued at discharge. To elucidate this hypothesis two
observational research studies were launched: Study A - to
follow plasma glutamine concentrations after ICU dis-
charge, and Study B - to find out if post-ICU plasma glu-
tamine concentration is a mortality predictor.
Methods
Patients
The unit has 12 beds and is the only ICU at the
Huddinge wing of Karolinska University Hospital, which
includes transplant surgery, major gastrointestinal sur-
gery, hematology and infectious diseases, but not cardiac
surgery, trauma care and neurosurgery. The protocol was
to include consecutive patients admitted to the general
ICU at Karolinska University Hospital Huddinge, who re-
ceived iv glutamine supplement for >3 days. Exclusion
criteria were: age <18, restrains of treatment, absence of
informed consent, and readmissions to the ICU. Patients
already in the study continued their enrollment accord-
ing to protocol - if they were readmitted. Figure 1
contains CONSORT diagrams on patient recruitment. Be-
fore obtaining patients’ written informed consent, patients
(or next of kin) were informed verbally and in writing
about the study and possible risks. The Regional Ethics
Committee in Stockholm approved the protocol, which
complied with the Helsinki Declaration.
Protocols
In study A (post-ICU temporal pattern of plasma glutam-
ine concentrations) an initial sample was taken during on-
going glutamine supplementation in the ICU <24 hours
before discharge. Thereafter, samples were taken every 5 to
7 days as long as patients stayed in the hospital. If patients
were readmitted to the ICU (and then given iv glutamine
supplementation), sampling continued as per protocol.
In study B (post-ICU concentration of plasma glutam-
ine as outcome predictor) a sample was taken between
24 and 72 hours after ICU discharge. All-cause mortality
was then recorded for 12 months. Some patients (n = 56)
were included in both study protocols.
Nutrition
During ICU admission the nutritional protocol was aligned
with the Scandinavian Glutamine Trial protocol [12]. All
patients were started on enteral nutrition as soon as no
contraindication was evident. In parallel with the start of
enteral nutrition iv glutamine supplementation was started.
Complementary parenteral nutrition was started if calorictarget (as per indirect calorimetry energy expenditure)
was not reached on day 5 of ICU stay. Glutamine sup-
plementation was administered as L-alanyl-L-glutamine
200 mg/ml in 100 mL containers (Dipeptiven, Fresenius,
Bad Homburg, Germany), 100 mL per 24 hours if <60 kg,
200 mL per 24 hours if >60 kg, and 300 mL if >80 kg and
in addition on continuous renal replacement therapy - as a
continuous infusion over 24 hours. Deviations from the
Scandinavian Glutamine Trial protocol were (i) postponing
of complementary parenteral nutrition until day 5, (ii) con-
stant infusion of the glutamine-containing dipeptide during
24 hours instead of 12 hours, and (iii) dosing of the dipep-
tide in body-weight intervals rather than per kg.
Analysis
As described earlier, high-pressure liquid chromatog-
raphy (HPLC) using an on-column derivatization with
ortho-phtaldialdehyde/3-mercaptopropionic acid (OPA/3-
MPA) was used to analyze the plasma glutamine concen-
tration [13].
Statistics
Fifty patients were planned for inclusion in study A
(post-ICU temporal pattern of plasma glutamine con-
centrations) and 100 patients in study B (post-ICU con-
centration of plasma glutamine as outcome predictor).
In study B, data from an earlier study over admission
plasma glutamine concentration as an outcome pre-
dictor, suggested that n = 100 would be sufficient be-
cause both studies A and B were limited to patients with a
longer time of ICU stay [2]. Values are given as medians
(25th, 75th percentiles). Pearson’s linear regression was
used for correlations, and Mann-Whitney and Wilcoxon
tests were used for comparisons between and within
groups. Proportions were analyzed by two-sided Fisher’s
exact test. Mortality predictors were assessed using univari-
ate logistic regression and stepwise forward multiple logis-
tic regression (NCSS 2007 (Hintze J, NCSS LLC, Kaysville,
UT, USA)).
Results
In study A (the post-ICU temporal pattern of plasma
glutamine concentrations) patients were included be-
tween October 19, 2011 and June 11, 2012 (Figure 1A).
Sixty-three patients were included to reach the target,
which resulted in 49 patients who could be evaluated
for their post-ICU plasma glutamine concentrations. For
patient characteristics see Table 1, and for ICU dis-
charge, total amino acids and glutamine concentrations
see Table 2. Figure 2 shows the plasma glutamine con-
centration in each patient. In subpanels B and C patients
are divided into (i) those who were readmitted or not re-
admitted to ICU, and (ii) survivors and nonsurvivors.
The glutamine supplementation periods are indicated for
Figure 1 CONSORT diagrams on patients screened and included in the studies. Patients admitted to the ICU) and given exogenous
intravenous glutamine supplementation together with full nutrition for >3 days were eligible. (A) describes patients sampled on their last day of
ICU stay and thereafter every 5 to 7 days during the remaining hospital stay. Mortality, dropouts and ICU readmissions are indicated. (B) describes
patients discharged from the ICU and sampled 24 to 72 hours after discharge. Mortality and dropouts are indicated. ICU, intensive care unit.
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collected: 6 were <400 μmol/L and 16 were >930 μmol/L.
Values outside these limits have been shown to be associ-
ated with an increased mortality risk at ICU admission [2].
At discharge from the ICU, plasma glutamine concentra-
tion dropped in 30 out of 49 patients from 690 (532,818)
to 622 (506,765) μmol/L (P = 0.054).
Regarding the samples collected during ongoing iv glu-
tamine supplementation on the last day of ICU stay all
63 patients were evaluated (Tables 1 and 3a,b), therewas a difference between 12-month survivors and non-
survivors, 596 (491,744) versus 777 (648,848) μmol/L
(P = 0.004) respectively (Figure 3A). There was also a dif-
ference in the sequential organ failure assessment (SOFA
score on the last day of ICU stay 3 (2,5) versus 7 (4,9)
(P = 0.0003). Using univariate logistic regression analysis,
discharge SOFA score, admission simplified acute physi-
ology score III (SAPS III) score, dialysis, and discharge
plasma glutamine concentration were identified as mortal-
ity predictors (Table 3a). The stepwise regression analysis
Table 1 Patient characteristics
Gender (male) Age (years) SAPS III LOS (days) SOFA discharge Dialysis
Study A (n = 63) 39 (62%) 64 (56,71) 68 (62,80) 9 (7,14) 4 (2,8) 13 (21%)
Study A (n = 49) 31 (63%) 63 (55,72) 68 (60,80) 9 (6,13) 4 (2,7) 10 (20%)
Survivors (n = 40) 26 (65%) 63 (56,71) 65 (62,74) 9 (6,13) 3 (2,5) 3 (8%)
Nonsurvivors (n = 23) 13 (56%) 65 (61,71) 71 (64,89) 8 (7,14) 7 (4,9) 10 (43%)
P value 0.59 0.62 0.042 0.81 0.00085 0.0012
Study B (n = 100) 58 (58%) 65 (56,72) 68 (61,77) 9 (6,14) 4 (2,6) 16 (16%)
Study B (n = 92) 55 (60%) 65 (56,72) 68 (62,78) 9 (6,13) 4 (2,7) 16 (17%)
Survivors (n = 54) 32 (60%) 65 (56,72) 65 (58,70) 8 (6,11) 3 (2,5) 6 (11%)
Nonsurvivors (n = 38) 23 (60%) 65 (60,72) 74 (66,88) 10 (6,16) 6 (2,8) 10 (26%)
P value 1.00 0.74 0.0013 0.15 0.043 0.09
All subjects included in Study A (n = 63) and subjects with post-ICU samples (n = 49), and all subjects included in Study B (n = 100) and subjects with post-ICU samples
(n = 92). Comparison of survivors and nonsurvivors was done in each group using Mann-Whitney or Fischer’s exact tests. SAPS III, simplified acute physiology score III;
LOS, length of stay; SOFA, sequential organ failure assessment.
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plemented the discharge plasma glutamine concentration
and enabled the best mortality prediction (Table 3b).
In study B (the post-ICU concentration of plasma
glutamine as outcome predictor), patients were in-
cluded between October 10, 2011 and March 27, 2013
(Figure 1B). The target was 100 patients, out of which 92
could be evaluated, for patient characteristics see Table 1,
and for post-ICU total amino acids and glutamine concen-
trations see Table 2. No difference in post-ICU plasma
glutamine concentration existed regarding 12-month, all-
cause mortality: 490 (397,604) versus 517 (418,675) μmol/L
(P = 0.45), for survivors (n = 54) and nonsurvivors (n = 38)
respectively (Figure 3B). Post-ICU plasma glutamine
concentration was not a significant mortality predictor
(Table 3c). In addition, there was no significant correl-






Study A (n = 63) 3.02 (2.61,3.36) 662 (524,796) 22.6 (19.2,24.5)
Study A (n = 49) 3.11 (2.63,3.34) 690 (532,818) 22.9 (19.2,26.0)
Survivors (n = 40) 2.85 (2.60,3.28) 596 (491,744) 22.5 (19.0,23.5)
Nonsurvivors (n = 23) 3.12 (2.75,3.67) 777 (648,848) 23.9 (21.9,26.7)
P value 0.12 0.0038 0.08
Study B (n = 92) 2.36 (2.02,2.95) 506 (414,658) 21.7 (17.8,24.1)
Survivors (n = 54) 2.29 (2.03,2.74) 490 (397,604) 21.3 (17.0,24.4)
Nonsurvivors (n = 38) 2.46 (1.98,3.02) 517 (418,675) 22.4 (19.3,23.9)
Odds ratio (95% CI) 0.99 (0.65-1.52) 1.001 (0.999-1.003) 1.03 (0.95-1.12)
P value 0.86 0.45 0.48
All subjects included in Study A (n = 63) with discharge samples and subjects
with consequent post-ICU samples (n = 49), and subjects included in Study B
with post-ICU samples (n = 92). Comparison of survivors and nonsurvivors was
done in each group using the Mann-Whitney test. CI, confidence interval.and discharge SOFA score, r = 0.07, (P = 0.51). Using uni-
variate regression analysis, discharge SOFA score as well
as admission SAPS III were identified as mortality predic-
tors, but not post-ICU plasma glutamine concentration
(Table 1c). The stepwise regression analysis indicated that
neither discharge SOFA score nor post-ICU plasma glu-
tamine concentration added any prediction value to ad-
mission SAPS III score, which gave the best mortality
prediction in this group of patients.
Discussion
The main findings from studies A and B were that post-
ICU plasma glutamine levels were within the normal
range and that they did not predict mortality. Not unex-
pectedly, admission SAPS III and discharge SOFA were
the strongest mortality predictors in this highly selected
subgroup of ICU patients. Remarkably, discharge plasma
glutamine concentration during ongoing intravenous sup-
plementation added prediction value - with a higher con-
centration within normal limits being more unfavorable.
The nutrition protocol was adapted from the protocol
used in the Scandinavian Glutamine Trial [12] because
hypotheses behind the present protocols were generated
from that trial. This, of course, limits the generalizability
of the findings. Eligible patients were supplemented
intravenously with a glutamine-containing dipeptide. The
objective was to normalize plasma glutamine levels.
Study A somewhat demonstrated that this objective was
achieved. Out of 63 patients sampled on the last day of
ICU stay during ongoing glutamine-containing infusing,
56 out of 63 were within the range 400 to 930 μmol/L, 3
were <400 μmol/L and 4 were >930 μmol/L. These limits
were chosen from an earlier study when glutamine levels
at admission were tested for outcomes prediction [2].
Sometimes the normal range in healthy subjects is given
as 500 to 850 μmol/L [13], but we thought the reference





































































































Figure 2 (See legend on next page.)
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Figure 2 Post-ICU plasma glutamine concentrations of patients (n = 49), admitted to the ICU and given exogenous intravenous
glutamine supplementation together with full nutrition for >3 days. Patients were sampled on their last day of ICU stay (during ongoing
intravenous supplementation) and thereafter every 5 to 7 days during the remaining hospital stay. All patients are depicted in (A). The reference
interval used in the study, 400 to 930 μmol/L is indicated by gray shading. (B) only illustrates patients who were not readmitted to ICU (n = 35),
where the nonsurvivors at 12 months (n = 7) are shown as red lines. (C) illustrates patients who were readmitted to the ICU (n = 14), nonsurvivors
at 12 months (n = 8) are shown as red lines. Thick lines illustrate periods during which patients in this subgroup were again given intravenous
glutamine supplementation during full feeding. ICU, intensive care unit.
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sion (among the studied mixed cases) may be of greater
relevance.
The hypothesis of post-ICU plasma glutamine concen-
tration as a mortality predictor could be dismissed in the
patient group that required a long ICU stay. Admission
SAPS III score was the best mortality predictor in this
selected group of patients, also at discharge. From these
data, there is no rational to treat patients with glutamine
supplementation post ICU. In general, post-ICU plasma
glutamine levels were not low, and they did not facilitate
mortality prediction. Yet patients with a glutamine defi-
ciency might exist, and determination of plasma glutamine
concentrations (or even better, determination of endogen-
ous glutamine production) should identify such patients.
Studies in this area might resolve this issue.
Supraphysiological plasma glutamine concentrations
are perhaps more common in critically ill patients than
earlier thought. In our observational study of admis-
sion glutamine levels, concentrations >930 μmol/L wereTable 3 Prediction of 12-month mortality in ICU patients that
supplementation
a. Univariate logistic regression analysis in group A, patients sampled at disch
OR (95% CI)
Discharge SOFA (per point) 1.38 (1.14-1.67)
Dialysis at discharge 9.49 (2.25-39.9)
Discharge P-glutamine (per μmol/L) 1.004 (1.001-1.007)
Admission SAPS III (per point) 1.041 (1.002-1.081)
Discharge total amino acids (per μmol/L) 1.0008 (1.0000-1.0016
b. Stepwise multiple logistic regression analysis in group A, patients sampled
β
Intercept −5.45
Discharge SOFA (per point) 0.335
Discharge P-glutamine (per μmol/L) 0.041
c. Univariate logistic regression analysis in group B, patients sampled 24–72 h
OR (95% CI)
Discharge SOFA (per point) 1.17 (1.02-1.34)
Post ICU P-glutamine (per μmol/L) 1.0008 (0.9985-1.0031
Admission SAPS III (per point) 1.06 (1.02-1.09)
ICU, intensive care unit; iv, intravenous; OR, odds ratio; CI, confidence interval; SOFA
physiology score III; β, regression coefficient; % correct, fraction correctly predictedassociated with an unfavorable outcome [2]. In acute ful-
minant liver failure similar supraphysiological glutamine
levels are quite common [14]. In an earlier publication,
we reported a case with an extremely high concentration,
which was normalized upon recovery [15].
In studies A and B, 16 out of 210 post-ICU samples
were supraphysiological. Out of these, 11 were during iv
glutamine supplementation in the ICU after readmis-
sion, and 5 were post ICU without any supplementation.
Of the supraphysiological values 7 out of 16 values were
recorded in 3 patients who survived and, 9 out of 16
values were recorded in 4 patients who did not survive
(Figure 2C). Most importantly, studies are needed to ex-
plain the relation between plasma glutamine concentra-
tion and the endogenous glutamine production in various
states of critical illness. Others have reported a higher
plasma glutamine concentration (within normal limits) in
nonsurviving long-staying ICU patients, but supraphysio-
logical concentrations of other amino acids were reported
to be stronger mortality predictors in that report [16].were discharged from ICU after >3 days of iv glutamine







at discharge and longitudinally post ICU (n = 63)
OR (95% CI) P % Correct
0.004 (0.0002-0.081)
1.40 (1.13-1.72) 0.0004 73.0
1.004 (1.001-1.008) 0.0043 76.2






























Figure 3 Plasma glutamine concentrations in ICU patients given exogenous intravenous glutamine supplementation together with
full nutrition for >3 days and who were discharged alive from ICU, in relation to 12-month, post-ICU mortality. (A) illustrates discharge
glutamine level (n = 63), and (B) illustrates glutamine levels 24 to 72 hours post discharge (n = 92). Discharge glutamine level during ongoing
intravenous supplementation but not post-ICU glutamine level was associated with mortality outcome. Gray shading indicates the reference
interval used, 400 to 930 μmol/L. Horizontal lines indicate median values. ICU, intensive care unit.
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supraphysiological levels of glutamine may be toxic. The
REDOX study reported a more unfavorable outcome
in ICU patients - given a hypocaloric diet containing
pharmacological doses of glutamine administered enter-
ally and intravenously [9]. But the plasma concentration
data from a small subgroup of these patients did not
reveal high glutamine values during treatment. So the
harm associated with glutamine supplementation in the
REDOX study was not associated with high plasma glu-
tamine concentrations in the reported data. In the ma-
terial from studies A and B, there is a signal from
individual subjects that high glutamine levels - regard-
less of supplementation - may be associated with an
unfavorable outcome. More clarity is needed whether
plasma glutamine concentration is an indicator of glu-
tamine depletion. Consequently, further studies over glu-
tamine kinetics (production and utilization) in relation
to plasma glutamine concentration are needed [17].
Particular interest has been given to kidney failure as a
possible association to high glutamine concentrations
and an unfavorable outcome [7]. Here we found dialysis
to be a mortality predictor at ICU discharge in Study A.
However, this statistical relationship was not maintained
in the multivariate analysis outside the prediction con-
tained in the discharge SOFA score. It must be emphasized
that these post hoc analyses are of a purely hypothesis-
generating character, and the statistical power contained in
these calculations is limited [18,19]. In particular, it may be
noted in Table 1 the difference in dialysis at discharge as
related to mortality between groups A and B, although
there were identical inclusion criteria and a considerableoverlap in recruitment between the two groups, underlin-
ing the hazards associated with post hoc analyses.
The strengths of studies A and B are that consecutive
patients were included and that 100% follow-up was
possible. The limitations are that the ICU patient case
mix may limit the generalizability of the result. Ongoing
intravenous glutamine supplementation during ICU stays
is also uncommon, but was part of the hypothesis follow-
ing the result of the Scandinavian Glutamine Trial [12].
Conclusions
ICU survivors were not low in plasma glutamine after
ICU discharge, although no exogenous supplementation
was given. In addition, post-ICU glutamine level was not
a mortality predictor in the way that admission glutam-
ine has been demonstrated to be. So after ICU discharge,
exogenous glutamine supplementation does not have the
same rationale as during ICU stay. At ICU discharge a
higher plasma glutamine level was associated with post-
ICU mortality. The possible indication for exogenous
glutamine supplementation during ICU stay is still not
properly defined.
Key messages
 Post-ICU plasma glutamine concentration in ICU
survivors is within normal range and it is not an
outcome predictor.
 Supranormal plasma concentrations of glutamine
were seen more often than expected. The
pathogenetic relevance of this finding must be
elucidated.
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